RegulatoryCompany release

Bicycle's nuzefatide pevedotin gets FDA orphan designation for pancreatic cancer as Q3 loss narrows

🇺🇸 Bicycle Therapeutics Plc (BCYC) · Thu 29 Oct 2026

The EphA2-targeting Bicycle Drug Conjugate received the US designation in September 2026, while the company reported $469.9 million in cash and a $10.5 million third-quarter net loss.

Bicycle Therapeutics has announced that the US Food and Drug Administration granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer. The company said the designation was awarded in September 2026. The product is an EphA2-targeting Bicycle Drug Conjugate.

A Phase 2 trial of nuzefatide pevedotin in recurrent pancreatic ductal adenocarcinoma is currently enrolling patients. Bicycle said it expects to provide updates from the study in 2027.

The designation was disclosed alongside the company's third-quarter 2026 results, reported on 29 October. Bicycle posted a net loss of $10.5 million for the quarter and held $469.9 million in cash. The company said this cash position is expected to fund operations into 2030.

For context, orphan designation in the US is granted to medicines intended for rare diseases and can bring benefits such as development incentives and potential market exclusivity if the product is later approved. It does not indicate that a product is safe or effective.

What it means for your team

  • Regulatory teams tracking pancreatic cancer pipelines can note a new US orphan designation for an EphA2-targeting conjugate; designation alone is not an approval or an efficacy signal.
  • The Phase 2 recurrent pancreatic ductal adenocarcinoma trial is still enrolling, with updates not expected until 2027, so clinical data are not imminent.
  • Bicycle's stated cash runway into 2030 suggests the programme is funded through the period covered by the company's guidance.

Company's press release (SEC filing): Bicycle Therapeutics Plc ↗

Article written by VigiEye from the official source (Bicycle Therapeutics Plc). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →